Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Operating Margin (2020 - 2025)

Historic Operating Margin for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 26.56%.

  • Evoke Pharma's Operating Margin rose 218800.0% to 26.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.99%, marking a year-over-year increase of 324600.0%. This contributed to the annual value of 50.77% for FY2024, which is 926600.0% up from last year.
  • As of Q3 2025, Evoke Pharma's Operating Margin stood at 26.56%, which was up 218800.0% from 41.55% recorded in Q2 2025.
  • Evoke Pharma's Operating Margin's 5-year high stood at 26.56% during Q3 2025, with a 5-year trough of 2864.88% in Q1 2021.
  • Moreover, its 5-year median value for Operating Margin was 157.72% (2023), whereas its average is 356.29%.
  • Per our database at Business Quant, Evoke Pharma's Operating Margin crashed by 2000000000bps in 2021 and then soared by 23746100bps in 2022.
  • Over the past 5 years, Evoke Pharma's Operating Margin (Quarter) stood at 429.14% in 2021, then soared by 50bps to 214.7% in 2022, then skyrocketed by 48bps to 112.64% in 2023, then soared by 68bps to 36.08% in 2024, then rose by 26bps to 26.56% in 2025.
  • Its Operating Margin stands at 26.56% for Q3 2025, versus 41.55% for Q2 2025 and 42.26% for Q1 2025.